| Literature DB >> 24977416 |
Evelyne Decullier1, Laure Huot1, François R Chapuis1.
Abstract
BACKGROUND: The fate of clinical research projects funded by a grant has been investigated, but there is no information on the projects which did not receive funding. The fate of these projects is not known: do they apply for and/or receive funding from other sources or are they carried out without specific funding?Entities:
Mesh:
Year: 2014 PMID: 24977416 PMCID: PMC4076181 DOI: 10.1371/journal.pone.0099561
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Initial characteristics of protocols submitted to the PHRC 2000 funding scheme (n = 481).
| Variable | Modality | n | % |
| Centres | Monocentre | 145 | 30 |
| Multicentre | 336 | 70 | |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
| Sample size provided | Yes | 415 | 86 |
| No | 66 | 14 | |
|
|
|
|
|
|
|
|
| |
|
|
|
| |
| Inclusion period provided | Yes | 239 | 50 |
| No | 242 | 50 | |
| Topic | Epidemiology | 133 | 28 |
| Act/Gesture/Technique | 74 | 16 | |
| Strategy | 64 | 13 | |
| Drug | 51 | 11 | |
| Cell/gene therapy | 43 | 9 | |
| Practice evaluation | 37 | 8 | |
| Medical device | 14 | 3 | |
| Other | 58 | 12 | |
| Study design | Descriptive | 100 | 21 |
| Analytic | 135 | 28 | |
| Experimental | 239 | 50 |
*Information available for 474 studies.
Fate of protocols according to funding*.
| Overall | PHRC 2000 | Chi2 p-value | PHRC 2000/other PHRC | Chi2 p-value | PHRC 2000/other PHRC/other funding | Chi2 p-value | |||||
| Funded | Not funded | Funded | Not funded | Funded | Not funded | ||||||
| Submitted | 481 | 101 | 380 | 138 | 343 | 175 | 306 | ||||
| Investigator response | Available | 366 | 87 (86) | 279 (73) | 123 (89) | 243 (71) | 160 (91) | 206 (67) | |||
| Not available | 115 | 14 (14) | 101 (27) | 15 (11) | 100 (29) | 15 (9) | 100 (33) | ||||
| Study initiated | No | 172 | 9 (10) | 163 (60) | <0.0001 | 15 (12) | 157 (67) | <0.0001 | 20 (13) | 152 (77) | <0.0001 |
| Yes | 185 | 77 (90) | 108 (40) | 107 (88) | 78 (33) | 139 (87) | 46 (23) | ||||
|
|
| ||||||||||
| Study completed | No | 64 | 23 (30) | 41 (38) | 0.28 | 31 (29) | 33 (42) | 0.06 | 43 (31) | 21 (46) | 0.08 |
| Yes | 121 | 54 (70) | 67 (62) | 76 (71) | 45 (58) | 96 (69) | 25 (54) | ||||
| Study published (of those initiated) | No | 70 | 28 (37) | 42 (39) | 0.88 | 39 (37) | 31 (40) | 0.76 | 47 (34) | 23 (50) | 0.08 |
| Yes | 113 | 47 (63) | 66 (61) | 66 (63) | 47 (60) | 90 (66) | 23 (50) | ||||
|
|
| ||||||||||
| Study published (of those completed) | No | 31 | 14 (27) | 17 (25) | 1.00 | 19 (26) | 12 (27) | 1.00 | 23 (24) | 8 (32) | 0.45 |
| Yes | 88 | 38 (73) | 50 (75) | 55 (74) | 33 (73) | 71 (76) | 17 (68) | ||||
|
|
| ||||||||||
Values are n (%).
*Information on PHRC 2000 funding was obtained from the French Ministry of Health, information on other funding was provided by the primary investigator (327 out of 366 provided information).
Figure 1Time to publication.